GTHX - G1 Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.79
-1.23 (-11.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.02
Open10.66
Bid0.00 x 1000
Ask0.00 x 800
Day's Range9.64 - 10.85
52 Week Range8.80 - 41.80
Volume252,750
Avg. Volume313,333
Market Cap368.517M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-3.27
Earnings DateFeb 25, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.60
  • Cover Story: Triangle life sciences gasping for capital, leaders
    American City Business Journals

    Cover Story: Triangle life sciences gasping for capital, leaders

    There's a growing consensus that the Triangle is not only strapped for the venture capital needed to make innovative ideas coming out of local universities work, but it is also severely lacking in the kind of corporate leadership needed to guide innovation to successful commercial companies.

  • GlobeNewswire

    G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO). “We are pleased to welcome Jack and Soma, and their breadth of commercial experience, as we work toward the approval of trilaciclib in small cell lung cancer,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer.

  • GlobeNewswire

    G1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial Update

    New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20Trilaciclib selected for inclusion in I-SPY 2 breast cancer trialRintodestrant.

  • Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus
    American City Business Journals

    Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus

    Global concerns over the spread of the novel coronavirus rocked stock markets on Monday. The spread of COVID-19 has been a major economic punch felt around the globe, and it's impacting production at Triangle firms – from Lenovo to Cree.

  • GlobeNewswire

    G1 Therapeutics to Present at Investor Conferences in March 2020

    RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate.

  • GlobeNewswire

    G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020

    RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.

  • GlobeNewswire

    G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020

    RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik,.

  • GlobeNewswire

    G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020

    RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

  • PR Newswire

    Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer

    Quantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy, in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

  • GlobeNewswire

    G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

  • GlobeNewswire

    G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvestrant for the treatment of estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. Updated findings presented during a poster session (P1-19-17) at the 2019 San Antonio Breast Cancer Symposium (SABCS) showed lerociclib, dosed without a drug holiday, has a differentiated safety and tolerability profile than observed in clinical trials with currently marketed CDK4/6 inhibitors.

  • GlobeNewswire

    G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

  • Thomson Reuters StreetEvents

    Edited Transcript of GTHX.O earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 G1 Therapeutics Inc Earnings Call

  • GlobeNewswire

    G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

  • We're Not Very Worried About G1 Therapeutics's (NASDAQ:GTHX) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About G1 Therapeutics's (NASDAQ:GTHX) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • 3 Biotech Stocks Needham Expects to Double in the Next 12 Months
    TipRanks

    3 Biotech Stocks Needham Expects to Double in the Next 12 Months

    Overall, the stock markets have been gaining in recent months. October saw a 2% bump for the general S&P 500 index, as did the Dow Jones average. But not all market segments are created equal, and some brought stronger returns for investors than others. The biotech industry, for example, had a particularly good month in the stock markets.The Biotech ETF, a sub-index of the NASDAQ that tracks the performance of stocks in the biotechnology and pharmaceutical sectors, rose 8% last month, four times the broader market’s average. The gains were led by the big names in the sector, but smaller stocks were also showing strength. Analysts from Needham, one of Wall Street’s top financial research firms, have picked out three small-cap biotechs that are showing a combination of recent gains and fantastic upside.Akcea Therapeutics (AKCA)A publicly traded company since July 2017, Akcea focuses on treatments for rare, serious diseases. The company’s main approved product, Tegsedi, treats “polyneuropathy caused by hereditary transthyretin-mediated amyloidosis” in adults. The drug is available in the US, Canada, and the EU. Waylivra, for the treatment of familial chylomicronemia syndrome, has been approved in the EU.Akcea has an active research pipeline with new drugs in all stages of testing, from pre-clinical to up to the FDA registration process. Most of Akcea’s products are for the treatment of cardiometabolic lipid disorders.In the Q3 earnings report, Akcea beat the EPS forecast by 38%, showing a net loss of 34 cents per share against the forecast 55 cents. In addition to beating the estimate, the quarterly EPS also showed a strong improvement from the year-ago quarterly loss of 58 cents. During the month of October, AKCA gained 24%, triple the overall biotech sector gains.Needham’s 4-star analyst Chad Messer writes of AKCA shares, “AKCA shares could go higher if the company can establish a pathway to approval for Waylivra with the FDA in FCS, if Waylivra reports positive data in FPL, or AKCEA-APOCIII-LRx, AKCEA-APO(a)-LRx, or AKECA-ANGPTL3-LRx report positive Phase II data. AKCA shares could also be driven higher by higher than expected sales for Tegsedi in FAP-ATTR.” Messer gives AKCA stock a $45 price target, implying a 127% upside and reflecting his optimism on the company’s path forward in the regulatory processes.With 3 recent Buy ratings, and only 1 Hold, AKCA has a Strong Buy from the analyst consensus. Shares sell for a modest $19.53, and the $40.50 average price target suggests an upside potential of 104%. (See Akcea stock analysis on TipRanks) Dermira (DERM)As its name suggests, Dermira is a pharmaceutical company focusing on dermatalogical issues, that is, on the treatment of chronic skin conditions. It’s easy to overlook, but the skin is the largest organ of the human body, and fills a wide range of rolls from keeping our insides in while keeping the outside out, to helping us regulate our body temperature.Dermira’s first approved products, Qbrexza, is a medicated cloth designed to treat hyperhidrosis – extreme sweating – in the armpits. The company also has Lebrikizumab, a treatment for atopic dermatitis, has just entered Phase 3 testing. Other projects are still in the pre-clinical testing phases.Like AKCA above, Dermira showed a strong Q3 despite operating at a net loss. The net loss per earning was $1.06, a 24% improvement from the expected EPS loss of $1.40. This marked the third time in the past year that DERM has beating the earnings forecast. The positive earnings news came after the stock had gained 15% in October.In a November 6 report on DERM, Needham analyst Serge Belanger focused on the company’s two main pharmaceutical products. He wrote, “The bulk of the recent DERM news flow revolved around lebrikizumab and its ph 3 program that got underway in mid-Oct. The 3Q19 financials and update mostly centered around the launch progression of Qbrexza, which generated sales of $10.2MM, surpassing Street expectations… Qbrexza is on pace to meet the low-$30MM 2019 sales guidance.”Belanger maintained his firm’s Buy rating on this stock, and gave it a $20 price target. His target implies a 185% potential to the upside.DERM gets a Strong Buy analyst consensus rating, with 3 Buys set in just the past week. The stock is a bargain price, at $7, but the potential of its new drugs and its research pipeline give it a high average price target of $19, and an impressively robust upside potential of 171%. (See Dermira stock analysis on TipRanks) G1 Therapeutics (GTHX)Once an almost certainly deadly, new treatments in recent years have brought hope to many cancer patients. G1 has a series of drugs in testing for small cell lung cancer, breast cancer, and colorectal cancer. The lung cancer treatments are in late stage testing and scheduled for regulatory submission in 2020. Also in 2020, the breast cancer and colorectal cancer treatments are scheduled to start trials.G1 shares were mostly flat in October, reflecting the differences between this company and the two listed above: where its peers above showed strong positive surprises in Q3 earnings, G1’s EPS loss was in line with estimates at 86 cents. Without any strong earnings surprise, and without any products post-approval, G1 did not shake up the expectations.Where this stock shines, however, is in long-term performance and forward potential. GTHX is up 20% year-to-date, a reflection of the hopes pinned on the latent possibilities of new cancer treatments. Chad Messer, quoted above, touches on this in his report on GTHX when he writes, “G1 remains on track to file a trilaciclib NDA and MAA in 2020 for myelopreservation in small cell lung cancer (SCLC). The next driver for GTHX is updated results from the Phase Ib study of lerociclib…” Messer’s price target of $74 suggests an upside of 223% to the stock – significantly higher than that implied for the stocks above.Messer is not the only analyst impressed by GTHX’s prospects in the cancer treatment research field. The stock has Buy ratings from 6 analysts recently, making its consensus rating a unanimous Strong Buy. Shares are trading for $22.82, and the average stock-price forecast of $65.50 indicates an upside potential of 169%. (See GTHX stock analysis on TipRanks)

  • GlobeNewswire

    G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update

    Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO.

  • GlobeNewswire

    G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019

    RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.

  • Here is What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX)
    Insider Monkey

    Here is What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 20% in 2019 (through September 30th). Conversely, hedge […]

  • Benzinga

    Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More

    The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence ...

  • GlobeNewswire

    G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary results from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. “Based on the promising safety and tolerability of G1T48 shown in this trial and the established efficacy of the SERD class, we believe that G1T48 has the potential to offer women with ER+, HER2- breast cancer an important new treatment option,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer. Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D added: “The FDA-approved SERD fulvestrant has been shown to be superior to aromatase inhibitors, the current standard of care in adjuvant ER+, HER2- breast cancer.

  • GlobeNewswire

    G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC). In the trial, median overall survival for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin (GC) was 20.1 months, compared with 12.6 months for patients receiving chemotherapy alone.

  • GlobeNewswire

    G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

    -  Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer.